Turning hepatic cancer stem cells inside out - a deeper understanding through multiple perspectives

Molecules and Cells

Volumn 38, Issue 3, 2015, Pages 202-209

  Chan, Lok Hei ^a   Luk, Steve T ^a   Ma, Stephanie ^a,b  

^a UNIVERSITY OF HONG KONG   (Hong Kong)

^b THE UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

Liver cancer; Microenvironment; Signaling; Therapeutic targeting; Tumor initiating cells

Indexed keywords

ARTICLE; CANCER MORTALITY; CANCER STEM CELL; CARCINOGENESIS; CARCINOGENICITY; DRUG RESISTANCE; GENE EXPRESSION; HUMAN; LIVER CANCER; LIVER CELL CARCINOMA; NONHUMAN; SIGNAL TRANSDUCTION; TUMOR MICROENVIRONMENT; UPREGULATION; ANIMAL; COMPLICATION; HEPATITIS B; HEPATITIS C; IMMUNOLOGY; LIVER NEOPLASMS; MOLECULARLY TARGETED THERAPY; PATHOLOGY; PHYSIOLOGY; VIROLOGY;

CYTOKINE;

ANIMALS; CYTOKINES; HEPATITIS B; HEPATITIS C; HUMANS; LIVER NEOPLASMS; MOLECULAR TARGETED THERAPY; NEOPLASTIC STEM CELLS; SIGNAL TRANSDUCTION; TUMOR MICROENVIRONMENT;

EID: 84938273951     PISSN: 10168478     EISSN: 02191032     Source Type: Journal    
DOI: 10.14348/molcells.2015.2356     Document Type: Article

References (76)

1. Akita, H., Marquardt, J.U., Durkin, M.E., Kitade, M., Seo, D., Conner, E.A., Andersen, J.B., Factor, V.M., and Thorgeirsson, S.S. (2014). MYC activates stem-like cell potential in hepatocarcinoma by a p53-dependent mechanism. Cancer Res. 74, 5903-5913.
2. Ali, N., Allam, H., May, R., Sureban, S.M., Bronze, M.S., Bader, T., Umar, S., Anant, S., and Houchen, C.W. (2011). Hepatitis C virus-induced cancer stem cell-like signatures in cell culture and murine tumor xenografts. J. Virol. 85, 12292-12303.
3. Altekruse, S.F., McGlynn, K.A., and Reichman, M.E. (2009). Hepatocellular carcinoma incidence, mortality, and survival trends in the United States from 1975 to 2005. J. Clin. Oncol. 27, 1485-1491.
4. Arzumanyan, A., Friedman, T., Ng, I., Clayton, M., Lian, Z., and Feitelson, M. (2011). Does the hepatitis B antigen HBx promote the appearance of liver cancer stem cells. Cancer Res. 71, 3701-3708.
5. Avila, M.A., Berasain, C., Torres, L., Martin-Duce, A., Corrales, F.J., Yang, H., Prieto, J., Lu, S.C., Caballeria, J., Rodes, J., et al. (2000). Reduced mRNA abundance of the main enzymes involved in methionine metabolism in human liver cirrhosis and hepatocellular carcinoma. J. Hepatol. 33, 907-914.
6. Bach, P., Abel, T., Hoffmann, C., Gal, Z., Braun, G., Voelker, I., Ball, C.R., Johnston, I.C., Lauer, U.M., Herold-Mende, C., et al. (2013). Specific elimination of CD133+ tumor cells with targeted oncolytic measles virus. Cancer Res. 73, 865-874.
7. Bartosch, B., Thimme, R., Blum, H.E., and Zoulim, F. (2009). Hepatitis C virus-induced hepatocarcinogenesis. J. Hepatol. 51, 810-820.
8. Cai, J., Sun, W.M., Hwang, J.J., Stain, S.C., and Lu, S.C. (1996). Changes in S-adenosylmethionine synthetase in human liver cancer: molecular characterization and significance. Hepatology 24, 1090-1097.
9. Chai, S., Tong, M., Ng, K.Y., Kwan, P.S., Chan, Y.P., Fung, T.M., Lee, T.K., Wong, N., Xie, D., Yuan, Y.F., et al. (2014). Regulatory role of miR-142-3p on the functional hepatic cancer stem cell marker CD133. Oncotarget 5, 5725-5735.
10. Chen, H., Luo, Z., Dong, L., Tan, Y., Yang, J., Feng, G., Wu, M., Li, Z., and Wang, H. (2013a). CD133/prominin-1-mediated autophagy and glucose uptake beneficial for hepatoma cell survival. PLoS One 8, e56878.
11. Chen, H., Luo, Z., Sun, W., Zhang, C., Sun, H., Zhao, N., Ding, J., Wu, M., Li, Z., and Wang, H. (2013b). Low glucose promotes CD133 mAb-elicited cell death via inhibition of autophagy in hepatocarcinoma cells. Cancer Lett. 336, 204-212.
12. Cheung, P.F., Cheng, C.K., Wong, N.C., Ho, J.C., Yip, C.W., Lui, V.C., Cheung, A.N., Fan, S.T., and Cheung, S.T. (2011). Granulin-epithelin precursor is an oncofetal protein defining hepatic cancer stem cells. PLoS One 6, e28246.
13. Chiba, T., Kita, K., Zheng, Y.W., Yokosuka, O., Saisho, H., Iwama, A., Nakauchi, H., and Taniguchi, H. (2006). Side population purified from hepatocellular carcinoma cells harbors cancer stem cell-like properties. Hepatology 44, 240-251.
14. Chiba, T., Suzuki, E., Negishi, M., Saraya, A., Miyagi, S., Konuma, T., Tanaka, S., Tada, M., Kanai, F., Imazeki, F. et al. (2012). 3- Deazaneplanocin A is a promising therapeutic agent for the eradication of tumor-initiating hepatocellular carcinoma cells. Int. J. Cancer 130, 2557-2567.
15. Chiba, T., Suzuki, E., Yuki, K., Zen, Y., Oshima, M., Miyagi, S., Saraya, A., Koide, S., Motoyama, T., Ogasawara, S. et al. Disulfiram eradicates tumor-initiating hepatocellular carcinoma cells in ROS-p38 MAPK pathway-dependent and - independent manners. PLoS One 9, e84807.
16. Ding, W., Mouzaki, M., You, H., Laird, J.C., Mato, J., Lu, S.C., and Rountree, C.B. (2009). CD133+ liver cancer stem cells from methionine adenosyl transferase 1A-deficient mice demonstrate resistance to transforming growth factor (TGF)-beta-induced apoptosis. Hepatology 49, 1277-1286.
17. Ezzeldin, M., Borrego-Diaz, E., Taha, M., Esfandyari, T., Wise, A.L., Peng, W., Rouyanian, A., Asvadi Kermani, A., Soleimani, M., Patrad, E., et al. (2014). RalA signaling pathway as a therapeutic target in hepatocellular carcinoma (HCC). Mol. Oncol. 8, 1043-1053.
18. Fan, Q.M., Jing, Y.Y., Yu, G.F., Kou, X.R., Ye, F., Gao, L., Li, R., Zhao, Q.D., Yang, Y., Lu, Z.H., et al. (2014). Tumor-associated macrophages promote cancer stem cell-like properties via transforming growth factor-beta1-induced epithelial-mesenchymal transition in hepatocellular carcinoma. Cancer Lett. 352, 160-168.
19. Gleiberman, A.S., Encinas, J.M., Mignone, J.L., Michurina, T., Rosenfeld, M.G., and Enikolopov, G. (2005). Expression of nestin-green fluorescent protein transgene marks oval cells in the adult liver. Dev. Dyn. 234, 413-421.
20. Hagiwara, S., Kudo, M., Nagai, T., Inoue, T., Ueshima, K., Nishida, N., Watanabe, T., and Sakurai, T. (2012). Activation of JNK and high expression level of CD133 predict a poor response to sorafenib in hepatocellular carcinoma. Br. J. Cancer 106, 1997-2003.
21. Haraguchi, N., Ishii, H., Mimori, K., Tanaka, F., Ohkuma, M., Kim, H.M., Akita, H., Takiuchi, D., Hatano, H., Nagano, H., et al. CD13 is a therapeutic target in human liver cancer stem cells. J. Clin. Invest. 120, 3326-3339.
22. He, G., Dhar, D., Nakagawa, H., Font-Burgada, J., Ogata, H., Jiang, Y., Shalapour, S., Seki, E., Yost, S.E., Jepsen, K., et al. (2013). Identification of liver cancer progenitors whose malignant progression depends on autocrine IL-6 signaling. Cell 155, 384-396.
23. Holczbauer, A., Factor, V.M., Andersen, J.B., Marquardt, J.U., Kleiner, D.E., Raggi, C., Kitade, M., Seo, D., Akita, H., Durkin, M.E., et al. (2013). Modeling pathogenesis of primary liver cancer in lineage-specific mouse cell types. Gastroenterology 145, 221-231.
24. Jemal, A., Bray, F., Center, M.M., Ferlay, J., Ward, E., and Forman, D. (2011). Global cancer statistics. cA Cancer J. Clin. 61, 69-90.
25. Kreso, A. and Dick, J.E. (2014). Evolution of the cancer stem cell model. Cell Stem Cell 14, 275-291.
26. Lai, K.P., Chen, J., He, M., Ching, A.K., Lau, C., Lai, P.B., To, K. F., and Wong, N. (2014). Overexpression of zFx confers self-renewal and chemoresistance properties in hepatocellular carcinoma. Int. J. Cancer 135, 1790-1799.
27. Lee, T.K., Castilho, A., Cheung, V.C., Tang, K.H., Ma, S., and Ng, I.O. (2011). CD24(+) liver tumor-initiating cells drive self-renewal and tumor initiation through STAT3-mediated NANOG regulation. Cell Stem Cell 9, 50-63.
28. Lee, T.K., Cheung, V.C., Lu, P., Lau, E.Y., Ma, S., Tang, K.H., Tong, M., Lo, J., and Ng, I.O. (2014a). Blockade of CD47-mediated cathepsin S/protease-activated receptor 2 signaling provides a therapeutic target for hepatocellular carcinoma. Hepatology 60, 179-191.
29. Lee, Y.H., Seo, D., Choi, K.J., Andersen, J.B., Won, M.A., Kitade, M., Gomez-Quiroz, L.E., Judge, A.D., Marquardt, J.U., Raggi, C., et al. (2014b). Antitumor effects in epatocarcinoma of isoform- selective inhibition of HDAC2. Cancer Res. 74, 4752-4761.
30. Levrero, M. (2006). Viral hepatitis and liver cancer: the case of hepatitis C. Oncogene 25, 3834-3847.
31. Li, C.H., Wang, Y.J., Dong, W., Xiang, S., Liang, H.F., Wang, H.Y., Dong, H.H., Chen, L., and Chen, X.P. (2011). Hepatic oval cell lines generate hepatocellular carcinoma following transfection with HBx gene and treatment with aflatoxin B1 in vivo. Cancer Lett. 311, 1-10.
32. Li, L., Liu, Y., Guo, Y., Liu, B., Zhao, Y., Li, P., Song, F., Zheng, H., Yu, J., Song, T., et al. (2014). Regulatory miR-148a-ACVR1/BMP circuit defines a cancer stem cell-like aggressive subtype of hepatocellular carcinoma. Hepatology [Epub ahead of print].
33. Liu, C., Liu, L., Shan, J., Shen, J., Xu, Y., Zhang, Q., Yang, Z., Wu, L., Xia, F., Bie, P., et al. (2013a). Histone deacetylase 3 participates in self-renewal of liver cancer stem cells through histone modification. Cancer Lett. 339, 60-69.
34. Liu, L., Yang, Z., Xu, Y., Li, J., Xu, D., Zhang, L., Sun, J., Xia, S., Zou, F., and Liu, Y. (2013b). Inhibition of oxidative stress-elicited AKT activation facilitates PPARgamma agonist-mediated inhibition of stem cell character and tumor growth of liver cancer cells. PLoS One 8, e73038.
35. Liu, A.Y., Cai, Y., Mao, Y., Lin, Y., Zheng, H., Wu, T., Huang, Y., Fang, X., Lin, S., Feng, Q., et al. (2014). Twist2 promotes selfrenewal of liver cancer stem-like cells by regulating CD24. Carcinogenesis 35, 537-545.
36. Ma, S., Chan, K.W., Hu, L., Lee, T.K., Wo, J.Y., Ng, I.O., Zheng, B.J., and Guan, X.Y. (2007). Identification and characterization of tumorigenic liver cancer stem/progenitor cells. Gastroenterology 132, 2542-2556.
37. Ma, S., Chan, K.W., Lee, T.K., Tang, K.H., Wo, J.Y., Zheng, B.J., and Guan, X.Y. (2008a). Aldehyde dehydrogenase discriminates the CD 133 liver cancer stem cell populations. Mol. Cancer Res. 6, 1146-1153.
38. Ma, S., Lee, T.K., Zheng, B.J., Chan, K.W., and Guan, X.Y. (2008b). CD 133+ HCC cancer stem cells confer chemoresistance by preferential expression of the Akt/PKB survival pathway. Oncogene 27, 1749-1758.
39. Ma, S., Tang, K.H., Chan, Y.P., Lee, T.K., Kwan, P.S., Castilho, A., Ng, I., Man, K., Wong, N., To, K.F., et al. (2010). miR-130b Promotes CD133(+) liver tumor-initiating cell growth and selfrenewal via tumor protein 53-induced nuclear protein 1. Cell Stem Cell 7, 694-707.
40. Marquardt, J.U., Raggi, C., Andersen, J.B., Seo, D., Avital, I., Geller, D., Lee, Y.H., Kitade, M., Holczbauer, A., Gillen, M.C., et al. (2011). Human hepatic cancer stem cells are characterized by common stemness traits and diverse oncogenic pathways. Hepatology 54, 1031-1042.
41. Martin-Padura, I., Marighetti, P., Agliano, A., Colombo, F., Larzabal, L., Redrado, M., Bleau, A.M., Prior, C., Bertolini, F., and Calvo, A. (2012). Residual dormant cancer stem-cell foci are responsible for tumor relapse after antiangiogenic metronomic therapy in hepatocellular carcinoma xenografts. Lab. Invest. 92, 952-966.
42. Mima, K., Okabe, H., Ishimoto, T., Hayashi, H., Nakagawa, S., Kuroki, H., Watanabe, M., Beppu, T., Tamada, M., Nagano, O., et al.(2012) . CD44s regulates the TGF-beta-mediated mesenchymal phenotype and is associated with poor prognosis in patients with hepatocellular carcinoma. Cancer Res. 72, 3414-3423.
43. Mokkapati, S., Niopek, K., Huang, L., Cunniff, K.J., Ruteshouser, E.C., deCaestecker, M., Finegold, M.J., and Huff, V. (2014). Beta- catenin activation in a novel liver progenitor cell type is sufficient to cause hepatocellular carcinoma and hepatoblastoma. Cancer Res. 74, 4515-4525.
44. Morris, S.M., Carter, K.T., Baek, J.Y., Koszarek, A., Yeh, M.M., Knoblaugh, S.E., and Grady, W.M. (2014). TGF-beta signaling alters the pattern of liver tumorigenesis induced by Pten inactivation. Oncogene [Epub ahead of print].
45. Neuveut, C., Wei, Y., and Buendia, M.A. (2010). Mechanisms of HBV-related hepatocarcinogenesis. J. Hepatol. 52, 594-604.
46. Nik-Zainal, S., Van Loo, P., Wedge, D.C., Alexandrov, L.B., Greenman, C.D., Lau, K.W., Raine, K., Jones, D., Marshall, J., Ramakrishna, M., et al. (2012). The life history of 21 breast cancers. Cell 149, 994-1007.
47. Piao, L.S., Hur, W., Kim, T.K., Hong, S.W., Kim, S.W., Choi, J.E., Sung, P.S., Song, M.J., Lee, B.C., Hwang, D., et al. (2012). CD 133+ liver cancer stem cells modulate radioresistance in human hepatocellular carcinoma. Cancer Lett. 315, 129-137.
48. Raggi, C., Factor, V.M., Seo, D., Holczbauer, A., Gillen, M.C., Marquardt, J.U., Andersen, J.B., Durkin, M., and Thorgeirsson, S.S. (2014). Epigenetic reprogramming modulates malignant properties of human liver cancer. Hepatology 59, 2251-2262.
49. Rountree, C.B., Senadheera, S., Mato, J.M., Crooks, G.M., and Lu, S.C. (2008). Expansion of liver cancer stem cells during aging in methionine adenosyltransferase 1A-deficient mice. Hepatology 47, 1288-1297.
50. Saito, T., Chiba, T., Yuki, K., Zen, Y., Oshima, M., Koide, S., Motoyama, T., Ogasawara, S., Suzuki, E., Ooka, Y. et al. . Metformin, a diabetes drug, eliminates tumor-initiating hepatocellular carcinoma cells. PLoS One 8, e70010.
51. Schrader, J., Gordon-Walker, T.T., Aucott, R.L., van Deemter, M., Quaas, A., Walsh, S., Benten, D., Forbes, S.J., Wells, R.G., and Iredale, J.P. (2011). Matrix stiffness modulates proliferation, chemotherapeutic response, and dormancy in hepatocellular carcinoma cells. Hepatology 53, 1192-1205.
52. Shan, J., Shen, J., Liu, L., Xia, F., Xu, C., Duan, G., Xu, Y., Ma, Q., Yang, Z., Zhang, Q., et al. (2012) Nanog regulates self-renewal of cancer stem cells through the insulin-like growth factor pathway in human hepatocellular carcinoma. Hepatology 56, 1004-1014.
53. Song, Y.J., Zhang, S.S., Guo, X.L., Sun, K., Han, Z.P., Li, R., Zhao, Q.D., Deng, W.J., Xie, X.Q., Zhang, J.W., et al. (2013). Autophagy contributes to the survival of CD133+ liver cancer stem cells in the hypoxic and nutrient-deprived tumor microenvironment. Cancer Lett. 339, 70-81.
54. Sosa, M.S., Bragado, P., and Aguirre-Ghiso, J.A. (2014). Mechanisms of disseminated cancer cell dormancy: an awakening field. Nat. Rev. Cancer 14, 611-622.
55. Sun, Z., Lu, P., Gail, M., Pee, D., Zhang, Q., Ming, L., Wang, J., Wu, Y., Liu, G., and Zhu, Y. (1999). Increased risk of hepatocellular carcinoma in male hepatitis B surface antigen carriers with chronic hepatitis who have detectable urinary aflatoxin metabolite M1. Hepatology 30, 379-383.
56. Sun, J.C., Pan, K., Chen, M.S., Wang, Q.J., Wang, H., Ma, H.Q., Li, Y.Q., Liang, X.T., Li, J.J., Zhao, J.J., et al. (2010). Dendritic cells-mediated CTLs targeting hepatocellular carcinoma stem cells. Cancer Biol. Ther. 10, 368-375.
57. Sun, Y.F., Xu, Y., Yang, X.R., Guo, W., Zhang, X., Qiu, S.J., Shi, R.Y., Hu, B., Zhou, J., and Fan, J. (2013). Circulating stem cell-like epithelial cell adhesion molecule-positive tumor cells indicate poor prognosis of hepatocellular carcinoma after curative resection. Hepatology 57, 1458-1468.
58. Tang, H., Delgermaa, L., Huang, F., Oishi, N., Liu, L., He, F., Zhao, L., and Murakami, S. (2005). The transcriptional transactivation function of HBx protein is important for its augmentation role in hepatitis B virus replication. J. Virol. 79, 5548-5556.
59. Tang, K.H., Ma, S., Lee, T.K., Chan, Y.P., Kwan, P.S., Tong, C.M., Ng, I.O., Man, K., To, K.F., Lai, P.B., et al. (2012). CD133(+) liver tumor-initiating cells promote tumor angiogenesis, growth, and self-renewal through neurotensin/interleukin-8/CXCL1 signaling. Hepatology 55, 807-820.
60. Tschaharganeh, D.F., Xue, W., Calvisi, D.F., Evert, M., Michurina, T.V., Dow, L.E., Banito, A., Katz, S.F., Kastenhuber, E.R., Weissmueller, S., et al. (2014). p53-dependent nestin regulation links tumor suppression to cellular plasticity in liver cancer. Cell 158, 579-592.
61. Wan, S., Zhao, E., Kryczek, I., Vatan, L., Sadovskaya, A., Ludema, G., Simeone, D.M., Zou, W., and Welling, T.H. (2014). Tumor- associated macrophages produce interleukin 6 and signal via STAT3 to promote expansion of human hepatocellular carcinoma stem cells. Gastroenterology 147, 1393-1404.
62. Wang, X.Q., Ongkeko, W.M., Chen, L., Yang, Z.F., Lu, P., Chen, K.K., Lopez, J.P., Poon, R.T., and Fan, S.T. (2010). Octamer 4 (Oct4) mediates chemotherapeutic drug resistance in liver cancer cells through a potential Oct4-AKT-ATP-binding cassette G2 pathway. Hepatology 52, 528-539.
63. Wang, C., Yang, W., Yan, H.X., Luo, T., Zhang, J., Tang, L., Wu, F.Q., Zhang, H.L., Yu, L.X., Zheng, L.Y., et al. (2012). Hepatitis B virus X (HBx) induces tumorigenicity of hepatic progenitor cells in 3,5-diethoxycarbonyl-1,4-dihydrocollidine-treated HBx transgenic mice. Hepatology 55, 108-120.
64. Wang, X.Q., Ng, R.K., Ming, X., Zhang, W., Chen, L., Chu, A.C., Pang, R., Lo, C.M., Tsao, S.W., Liu, X., et al. (2013). Epigenetic regulation of pluripotent genes mediates stem cell features in human hepatocellular carcinoma and cancer cell lines. PLoS One 8, e72435.
65. Wu, K., Ding, J., Chen, C., Sun, W., Ning, B.F., Wen, W., Huang, L., Han, T., Yang, W., Wang, C., et al. (2012). Hepatic transforming growth factor beta gives rise to tumor-initiating cells and promotes liver cancer development. Hepatology 56, 2255-2267.
66. Wurmbach, E., Chen, Y.B., Khitrov, G., Zhang, W., Roayaie, S., Schwartz, M., Fiel, I., Thung, S., Mazzaferro, V., Bruix, J., et al. (2007). Genome-wide molecular profiles of HCV-induced dysplasia and hepatocellular carcinoma. Hepatology 45, 938-947
67. Xia, H., Ooi, L.L., and Hui, K.M. (2013). MicroRNA-216a/217- induced epithelial-mesenchymal transition targets PTEN and SMAD7 to promote drug resistance and recurrence of liver cancer. Hepatology 58, 629-641.
68. Xu, X., Xing, B., Hu, M., Xu, Z., Xie, Y., Dai, G., Gu, J., Wang, Y., and Zhang, Z. (2010). Recurrent hepatocellular carcinoma cells with stem cell-like properties: possible targets for immunotherapy. Cytotherapy 12, 190-200.
69. Yamashita, T., Ji, J., Budhu, A., Forgues, M., Yang, W., Wang, H.Y., Jia, H., Ye, Q., Qin, L.X., Wauthier, E., et al. (2009). EpCAM- positive hepatocellular carcinoma cells are tumor-initiating cells with stem/progenitor cell features. Gastroenterology 136, 1012-1024.
70. Yang, Z.F., Ho, D.W., Ng, M.N., Lau, C.K., Yu, W.C., Ngai, P., Chu, P.W., Lam, C.T., Poon, R.T., and Fan, S.T. (2008). Significance of CD90+ cancer stem cells in human liver cancer. Cancer Cell 13, 153-166.
71. Yang, Z., Zhang, L., Ma, A., Liu, L., Li, J., Gu, J., and Liu, Y. (2011). Transient mTOR inhibition facilitates continuous growth of liver tumors by modulating the maintenance of CD133+ cell populations. PLoS One 6, e28405.
72. Yang, W., Wang, C., Lin, Y., Liu, Q., Yu, L.X., Tang, L., Yan, H.X., Fu, J., Chen, Y., Zhang, H.L., et al. (2012). OV6(+) tumor- initiating cells contribute to tumor progression and invasion in human hepatocellular carcinoma. J. Hepatol. 57, 613-620.
73. You, H., Ding, W., and Rountree, C.B. (2010). Epigenetic regulation of cancer stem cell marker CD133 by transforming growth factor-beta. Hepatology 51, 1635-1644.
74. Zhang, L., Sun, H., Zhao, F., Lu, P., Ge, C., Li, H., Hou, H., Yan, M., Chen, T., Jiang, G., et al. (2012). BMP4 administration induces differentiation of CD133+ hepatic cancer stem cells, blocking their contributions to hepatocellular carcinoma. Cancer Res. 72, 4276-4285.
75. Zhang, L., Li, H., Ge, C., Li, M., Zhao, F.Y., Hou, H.L., Zhu, M.X., Tian, H., Zhang, L.X., Chen, T.Y., et al. (2014). Inhibitory effects of transcription factor Ikaros on the expression of liver cancer stem cell marker CD 133 in hepatocellular carcinoma. Oncotarget 15, 10621-10635.
76. Zhao, W., Wang, L., Han, H., Jin, K., Lin, N., Guo, T., Chen, Y., Cheng, H., Lu, F., Fang, W. et al. (2013). 1B50-1, a mAb raised against recurrent tumor cells, targets liver tumor-initiating cells by binding to the calcium channel a2S1 subunit. Cancer Cell 23, 541-556.